Critical Care Trauma Centre

ETOMIDATE (Amidate)

 

 
Name: ETOMIDATE (AmidateR)
Classification: sedative-hypnotic
  • used as induction agent for intubation as general sedative or in rapid sequence induction
  • rapid onset of action usually within 60 seconds (may be 5-15 seconds) with duration of action of 3-5 minutes (may be up to 14 minutes)
  • no analgesic activity; minimal respiratory or cardiovascular effects
  • special access product
Dose:
  • 0.3 mg/kg to usual maximum of 20 mg IV
  • may require dose reduction in elderly patients
Administration: IV direct over 30-60 seconds
  • use large proximal arm veins or central line if possible to avoid pain on injection
Adverse Effects:
  • injection site pain
  • transient skeletal muscle movements including myoclonus
  • hypo-/hyperventilation, apnea
  • arrhythmias
  • laryngospasm
  • nausea/vomiting
  • prolonged suppression of cortisol and aldosterone synthesis with continuous infusion or repeated dosing
Monitoring Therapy:
  • continuous heart rate and rhythm
  • blood pressure
  • respiratory rate
  • Oxygen saturation
  • End-tidal CO2
Adult Critical Care Protocol:
  • Must be administered by MD trained in airway management with patient specific approval from senior resident or CCTC consultant.
  • monitoring sheet must be completed by administering physician and returned to Pharmacy Department.


Lynne Kelly, Pharmacist, CCTC
Brenda Morgan, Clinical Nurse Specialist, CCTC
Last Reviewed: September 20, 2018